Beinaglutide is another short-acting recombinant human GLP-1RA that closely resembles human GLP-1(6-37), approved in China for the indications of type 2 diabetes mellitus and weight loss
Limitations and Considerations BMI cutoff used is in between the typical cutoffs for overweight and obese Limited generalizability given that the majority of patients included were Caucasian, with only 12.5% African American male predominant population studied, with only 27.7% females It remains to be demonstrated if treatment with semaglutide has a cardioprotective and preventative benefit in patients who do not have pre-existing cardiovascular disease PowellWiley TM, Poirier P, Burke LE, et al
Personalized Dosage and Administration Personalized dosage plans are essential for achieving optimal weight loss outcomes with retatrutide
Retatrutide's real advantage over older GLP-1 agonists is the 7-day half-life, which makes timing forgiveness built into the molecule
Once the medication is prescribed, your physician will instruct you on how much medication to administer weekly
Published in the New England Journal of Medicine, the trial tested retatrutide at doses of 1mg, 4mg, 8mg, and 12mg against placebo over 48 weeks
%25201.png)
